NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









MEPSGEN

MEPSGEN

Private
SeoulHealthcare & Life Scienceshttps://mepsgen.com/

Last Round

Series C

Nov 19, 2024

Total Funding Raised

$29.26M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

MEPSGEN is a biotechnology company that develops human microphysiological systems (organ-on-a-chip) and nanoparticle synthesis platforms to aid in drug discovery and development.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Devices, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

organ-on-a-chipmicrophysiological systemsMPSmicrofluidicsdrug discoverytoxicity testingin vitro modelslab-on-a-chipcontract researchautomated tissue cultureparticle synthesisbiotech equipmenttissue engineeringpersonalized medicineCRO services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MEPSGEN Comparables

Compare MEPSGEN with similar companies based on industry and business-model similarity.

MEPSGEN comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MIMETAS
86%
InSphero
85%
NETRI
85%

MEPSGEN Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 19, 2024
Series BJul 1, 2022
Series A ExtensionAug 1, 2021
Series AAug 1, 2020
AngelOct 1, 2019

Key People

Founding team and executive leadership

Hoon Suk Rho

Chief Technology Officer

Executive Team

MEPSGEN Investors

Notable investors and investment history

MEPSGEN investors
InvestorRounds
KIWOOM Securities Co., Ltd.Series B
SBI Investment KoreaSeries C, Series A Extension
KB SecuritiesSeries C
Kolon InvestmentSeries B
Kolon InvestmentSeries B
Yuanta InvestmentSeries C
Korea Development BankSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 29, 2026

    Open roles increased to 22, 6x the trailing average.

  • Jun 22, 2026

    Open roles increased from 0 to 11, representing 32% of headcount.

MEPSGEN Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

MEPSGEN Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MEPSGEN's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeoul
Employee Range31
Year Founded2019
Last FundingNov 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.